眼科新进展
眼科新進展
안과신진전
RECENT ADVANCES IN OPHTHALMOLOGY
2001年
2期
75-77
,共3页
谢立信%李绍伟%董晓光%袁凤波
謝立信%李紹偉%董曉光%袁鳳波
사립신%리소위%동효광%원봉파
HLA%PCR%角膜移植%免疫排斥
HLA%PCR%角膜移植%免疫排斥
HLA%PCR%각막이식%면역배척
HLA%PCR%corneal transplantation%rejection
目的 评价HLA基因配型在减少高危角膜移植免疫排斥反应中的作用。方法 对91例高危穿透性角膜移植病例，术后双盲法进行供受体HLA-DRB1基因分型和临床观察，随访12～26mo，对其基因配型情况和术后排斥反应的关系进行回顾性分析。结果 91例患者中61例随访资料完整。其中16例供受体有1个基因位点相符，在这些配型良好的病例中，5例(31.24%)发生免疫排斥反应，但随访期间无植片混浊；45例配型不好的患者中，术后23例(51.11%)发生免疫排斥反应，其中5例发生了植片混浊。结论 HLA-DRB1基因配型未能显著减少角膜移植术后的免疫排斥反应。
目的 評價HLA基因配型在減少高危角膜移植免疫排斥反應中的作用。方法 對91例高危穿透性角膜移植病例，術後雙盲法進行供受體HLA-DRB1基因分型和臨床觀察，隨訪12～26mo，對其基因配型情況和術後排斥反應的關繫進行迴顧性分析。結果 91例患者中61例隨訪資料完整。其中16例供受體有1箇基因位點相符，在這些配型良好的病例中，5例(31.24%)髮生免疫排斥反應，但隨訪期間無植片混濁；45例配型不好的患者中，術後23例(51.11%)髮生免疫排斥反應，其中5例髮生瞭植片混濁。結論 HLA-DRB1基因配型未能顯著減少角膜移植術後的免疫排斥反應。
목적 평개HLA기인배형재감소고위각막이식면역배척반응중적작용。방법 대91례고위천투성각막이식병례，술후쌍맹법진행공수체HLA-DRB1기인분형화림상관찰，수방12～26mo，대기기인배형정황화술후배척반응적관계진행회고성분석。결과 91례환자중61례수방자료완정。기중16례공수체유1개기인위점상부，재저사배형량호적병례중，5례(31.24%)발생면역배척반응，단수방기간무식편혼탁；45례배형불호적환자중，술후23례(51.11%)발생면역배척반응，기중5례발생료식편혼탁。결론 HLA-DRB1기인배형미능현저감소각막이식술후적면역배척반응。
Objective To evaluate the efficacy of the use of HLA-DRB1 genetictyping in high risk corneal transplantation.Methods Total of 91 high risk penetrating keratoplasty(PKP) patients were enrolled in this double masked study. HLA-DRB1 genetic typing was performed for both donors and recipients immediately after PKP, and were followed up for 12 to 26 months using a double masked design. The correlation between the graft rejection and HLA-DRB1 matching was analysed retrospectively.Results Sixty-one of 91 cases had complete follow-up data. Only 5 of 16 (31.24%)well-matched patients (1 gene loci matched)had graft rejection during the study period with no grafts failure. In 45 poor matched patients, 23 of 45 (51.11%)had more than one episode of rejection with 5 grafts failure.Conclusion Good HLA-DRB1 matching did not result in the reduction of the corneal graft rejection.
